Kite, unit today presented the latest results that demonstrate a 79% overall response rate (ORR) and 74% overall survival (OS ...

executive vice president and global head of Gilead Sciences' Kite, told Fierce Biotech at the American Society of Clinical Oncology conference in Chicago. The company is currently deciding between ...

Richard Wang has been named as chief executive of the joint venture, named Fosun Kite Biotechnology. Wang has extensive experience in the industry including roles at Procter & Gamble ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. | Following a ...

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit. Kite has agreed to acquire all ...

Low tax along with the quality of life and a drop in crime are drawing white-collar industries to the Florida city ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

Data from the POLARGO trial potentially establishes a new standard of care for patients with R/R DLBCL ineligible for ...

Analysts at Truist Securities called J&J’s CAR-T readout “compelling,” noting that the efficacy figures could position the ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...